Abrocitinib Bests Placebo for Treatment of Atopic Dermatitis

WEDNESDAY, March 24, 2021 -- For moderate-to-severe atopic dermatitis, the oral Janus kinase 1 (JAK1) inhibitor abrocitinib at 200 mg or 100 mg once daily results in significantly greater reductions in signs and symptoms versus placebo, according to...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news